Volpara Health, a New Zealand-based software company providing personalized breast and lung care, has expanded its footprint in the U.S. lung screening market with a strategic relationship with Seattle-based lung AI company RevealDx. This follows Volpara’s recent collaboration agreement with Miamisburg, Ohio-based lung imaging company Riverain Technologies.

Approximately, 20%-30% of lung CT exams reveal lung nodules which need to be characterized as benign or malignant. The workup typically may include a follow-up lung CT exam in a few months or a surgical biopsy. In addition, many lung nodules are found incidentally when CT exams are performed for other reasons, such as shortness of breath, chest pain, or injury.

Volpara Lung software—an integrated reporting, tracking, and risk assessment technology for lung cancer screening—enables patient management from scheduling to diagnosis. The software offers structured reporting, customizable reminders, and more than 40 statistical reports to monitor and track patients—critical for outreach to patients overdue for their screening or follow-up exams. Volpara Lung automatically collects and validates all the required data elements for successful submission to the American College of Radiology Lung Cancer Screening Registryfor reimbursement.

RevealDx, formerly known as Mindshare Medical, is focused on improving lung cancer outcomes by delivering the most advanced, radiomics and artificial intelligence (AI)-enabled, lung cancer decision-support software to drive the optimal clinical pathway for each patient based on automated analytics of each lung nodule. Its CE-marked software product integrates with PACS technologies and scores nodules found in lung CT, informing better clinical decision making.

Early clinical data for RevealAI-Lung suggests that many cancers can be detected earlier by using the AI nodule analysis rather than waiting for a scan in a few months’ time, while simultaneously reducing false positives.

“When we acquired MRS, we entered the lung cancer screening market with practice management software covering about 8% of the U.S. lung cancer screening market. Since then, the benefits of lung cancer screening using low-dose CT have become more widely accepted globally, with the U.S. doubling the number of people eligible, and countries like Australia starting the process of scoping out nationwide programs,” says Ralph Highnam, PhD, Volpara’s group CEO.

Chris Wood, RevealDx CEO, also spoke out about the partnership, commenting: “Volpara has a solid market hare in lung, and we look forward to working closely with them to fully integrate RevealDx’s AI capabilities into a wider lung offering both here in the United States and into Australia and New Zealand. The ability to diagnose early, inform treatments, and optimize the total cost of care will be a game-changer.”